|Articles|September 22, 2015

Jenna Earl

Jenna Ealr is Senior Consultant at Blue Latitude

http://bluelatitude.net/about-us-strategic-marketing-consultants/jenna/

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: FDA Approves Auvelity

ByNicholas Jacobus

May 1st 2026

FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap

ByNicholas Jacobus

May 1st 2026

Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman

ByNicholas Jacobus,Jeff Golfman

May 1st 2026

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

ByNicholas Jacobus

May 1st 2026

Asembia ASX26: Payers and the Rising Costs for Cell & Gene Therapies

ByMike Hollan,Will Shrank

May 1st 2026

Jenna Earl

Newsletter

Related Content

Pharmaceutical Executive Daily: FDA Approves Auvelity

FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap

Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

Asembia ASX26: Payers and the Rising Costs for Cell & Gene Therapies

Trending on PharmExec

Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?

Using a Customer-Based Process to Synchronize Sales & Marketing Organizations in Pharma

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote

FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap